134 related articles for article (PubMed ID: 38230990)
61. Diffuse large B-cell lymphoma with concurrent hepatitis B virus infection in the MabThera era: Unique clinical features and worse outcomes.
Yan X; Zhou M; Lou Z; Mu Q; Sheng L; Zhang P; Wang Y; Ouyang G
J Cancer Res Ther; 2018; 14(Supplement):S248-S253. PubMed ID: 29578182
[TBL] [Abstract][Full Text] [Related]
62. Chidamide combined with ibrutinib improved the prognosis of primary bone marrow diffuse large B cell lymphoma.
Tian C; Chen Z; Li Y
J Int Med Res; 2020 Jul; 48(7):300060520936053. PubMed ID: 32643971
[TBL] [Abstract][Full Text] [Related]
63. A population-based multistate model for diffuse large B-cell lymphoma-specific mortality in older patients.
Çağlayan Ç; Goldstein JS; Ayer T; Rai A; Flowers CR
Cancer; 2019 Jun; 125(11):1837-1847. PubMed ID: 30707765
[TBL] [Abstract][Full Text] [Related]
64. The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma: a propensity score matching analysis.
Nishimori H; Matsuo K; Maeda Y; Nawa Y; Sunami K; Togitani K; Takimoto H; Hiramatsu Y; Kiguchi T; Yano T; Yamane H; Tabayashi T; Takeuchi M; Makita M; Sezaki N; Yamasuji Y; Sugiyama H; Tabuchi T; Kataoka I; Fujii N; Ishimaru F; Shinagawa K; Ikeda K; Hara M; Yoshino T; Tanimoto M;
Int J Hematol; 2009 Apr; 89(3):326-331. PubMed ID: 19326060
[TBL] [Abstract][Full Text] [Related]
65. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.
Seo S; Hong JY; Yoon S; Yoo C; Park JH; Lee JB; Park CS; Huh J; Lee Y; Kim KW; Ryu JS; Kim SJ; Kim WS; Yoon DH; Suh C
Oncotarget; 2016 Nov; 7(47):76934-76943. PubMed ID: 27764777
[TBL] [Abstract][Full Text] [Related]
66. New developments in the management of diffuse large B-cell lymphoma.
Habermann TM
Hematology; 2012 Apr; 17 Suppl 1():S93-7. PubMed ID: 22507791
[TBL] [Abstract][Full Text] [Related]
67. [Aidi Injection-Asisted R-CHOP Chemotherapy for the Treatment of Diffuse Large B-Cell Lymphoma].
Lu GQ; Zhou XH; Chen H; Tan JP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Jun; 24(3):733-7. PubMed ID: 27342500
[TBL] [Abstract][Full Text] [Related]
68. 90Y-Ibritumomab Tiuxetan consolidation after autologous stem cell transplantation improves survival of patients with intermediate-/high-risk diffuse large B-cell lymphoma not responding adequately to first-line treatment.
Mondello P; Pitini V; Arrigo C; Derenzini E; Mian M
Anticancer Res; 2014 Sep; 34(9):5121-5. PubMed ID: 25202102
[TBL] [Abstract][Full Text] [Related]
69. Prevalence and clinicopathologic features of CD30-positive de novo diffuse large B-cell lymphoma in Chinese patients: a retrospective study of 232 cases.
Gong QX; Lu TX; Liu C; Wang Z; Liang JH; Xu W; Li JY; Zhang ZH; Chen Q
Int J Clin Exp Pathol; 2015; 8(12):15825-35. PubMed ID: 26884853
[TBL] [Abstract][Full Text] [Related]
70. Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era.
Kridel R; Telio D; Villa D; Sehn LH; Gerrie AS; Shenkier T; Klasa R; Slack GW; Tan K; Gascoyne RD; Connors JM; Savage KJ
Br J Haematol; 2017 Jan; 176(2):210-221. PubMed ID: 27739058
[TBL] [Abstract][Full Text] [Related]
71. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R
Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884
[TBL] [Abstract][Full Text] [Related]
72. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
73. The multilobated morphology is still a better prognosis factor of diffuse large B-cell lymphoma in the R-CHOP era.
Ito A; Miyaoka M; Tomita S; Ikoma H; Hiraiwa S; Carreras J; Kikuti YY; Kawada H; Nakamura N
Pathol Int; 2022 Nov; 72(11):550-557. PubMed ID: 36218197
[TBL] [Abstract][Full Text] [Related]
74. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
Tai WM; Chung J; Tang PL; Koo YX; Hou X; Tay KW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246
[TBL] [Abstract][Full Text] [Related]
75. Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma.
Wöhrer S; Püspök A; Drach J; Hejna M; Chott A; Raderer M
Ann Oncol; 2004 Jul; 15(7):1086-90. PubMed ID: 15205203
[TBL] [Abstract][Full Text] [Related]
76. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Poeschel V; Held G; Ziepert M; Witzens-Harig M; Holte H; Thurner L; Borchmann P; Viardot A; Soekler M; Keller U; Schmidt C; Truemper L; Mahlberg R; Marks R; Hoeffkes HG; Metzner B; Dierlamm J; Frickhofen N; Haenel M; Neubauer A; Kneba M; Merli F; Tucci A; de Nully Brown P; Federico M; Lengfelder E; di Rocco A; Trappe R; Rosenwald A; Berdel C; Maisenhoelder M; Shpilberg O; Amam J; Christofyllakis K; Hartmann F; Murawski N; Stilgenbauer S; Nickelsen M; Wulf G; Glass B; Schmitz N; Altmann B; Loeffler M; Pfreundschuh M; ;
Lancet; 2019 Dec; 394(10216):2271-2281. PubMed ID: 31868632
[TBL] [Abstract][Full Text] [Related]
77. Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas.
Cortelazzo S; Tarella C; Gianni AM; Ladetto M; Barbui AM; Rossi A; Gritti G; Corradini P; Di Nicola M; Patti C; Mulé A; Zanni M; Zoli V; Billio A; Piccin A; Negri G; Castellino C; Di Raimondo F; Ferreri AJ; Benedetti F; La Nasa G; Gini G; Trentin L; Frezzato M; Flenghi L; Falorio S; Chilosi M; Bruna R; Tabanelli V; Pileri S; Masciulli A; Delaini F; Boschini C; Rambaldi A
J Clin Oncol; 2016 Nov; 34(33):4015-4022. PubMed ID: 28199143
[TBL] [Abstract][Full Text] [Related]
78. Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP.
Wang Y; Li YJ; Jiang WQ; Rao HL; Huang JJ; Xia Y; Bi X; Sun P; Huang HQ; Lin TY; Guan ZZ; Li ZM
Ann Hematol; 2015 Nov; 94(11):1865-73. PubMed ID: 26327569
[TBL] [Abstract][Full Text] [Related]
79. Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma; a population-based analysis.
Meeuwes FO; Brink M; van der Poel MWM; Kersten MJ; Wondergem M; Mutsaers PGNJ; Böhmer L; Woei-A-Jin S; Visser O; Oostvogels R; Jansen PM; Diepstra A; Snijders TJF; Plattel WJ; Huls GA; Vermaat JSP; Nijland M
Eur J Cancer; 2022 Nov; 176():100-109. PubMed ID: 36208568
[TBL] [Abstract][Full Text] [Related]
80. Impact of high-dose chemotherapy and autologous transplantation as first-line therapy on the survival of high-risk diffuse large B cell lymphoma patients: a single-center study in Japan.
Inano S; Iwasaki M; Iwamoto Y; Sueki Y; Fukunaga A; Yanagita S; Arima N
Int J Hematol; 2014 Feb; 99(2):162-8. PubMed ID: 24338743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]